Connect Sign In
Calcitonin
Ordering Recommendation
Use to diagnose and monitor medullary thyroid carcinoma (MTC). Secondary test to assist in diagnosing multiple endocrine neoplasia type II and familial MTC.
New York DOH Approval Status
Specimen Required
Serum separator tube or green (sodium or lithium heparin).
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 2 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 1 mL)
Refrigerated.
Tissue or urine. EDTA plasma. Grossly hemolyzed or lipemic specimens.
After separation from cells: Ambient: 8 hours; Refrigerated: 1 week; Frozen: 3 months
Methodology
Quantitative Chemiluminescent Immunoassay
Performed
Sun-Sat
Reported
1-2 days
Reference Interval
Male 3 years and older: 0.0-7.5 pg/mL
Female 3 years and older: 0.0-5.1 pg/mL
Interpretive Data
Calcitonin levels greater than 100 pg/mL may occur in the following conditions: medullary thyroid carcinomas (MTC), leukemias, and myeloproliferative disorders.
Provocative testing (calcium) is suggested in patients with MTC if the calcitonin is not clearly diagnostic.
The Siemens Immulite® 2000 method is used. Results obtained with different assay methods or kits cannot be used interchangeably. Calcitonin is useful in monitoring medullary thyroid carcinoma. The calcitonin assay value, regardless of level, should not be interpreted as absolute evidence of the presence or absence of malignant disease.
FDA
Note
Hotline History
CPT Codes
82308
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0070006 | Calcitonin | 1992-7 |
Aliases
- Human Calcitonin
- Thyrocalcitonin
